Trimetazidine (TMZ) is a medication used to treat heart-related conditions like angina. It helps metabolize fatty acids, which helps your body use oxygen. The drug allows for more blood flow to ...

* Neurocrine Biosciences Inc - has been advised that PDUFA goal date is october 14, 2017 for Ingrezza 80 mg capsules - sec filing Source text for Eikon: Further company coverage: Sign up here ...

Both 40 mg and 80 mg doses of INGREZZA showed significant improvements in AIMS total scores, with mean baseline scores of 12.4 (40 mg) and 15.1 (80 mg) decreasing to 2.1 and 2.5, respectively, at ...

Controversy surrounding Russian figure skater Kamila Valieva’s failed drug test, which was taken in December but has only come to light during the Winter Olympics in Beijing, continues to delay ...

Cite this: Anti-Ischaemic Efficacy and Tolerability of Trimetazidine in Elderly Patients With Angina Pectoris - Medscape - Jan 01, 2000. Abstract and Introduction Patients and Methods ...

Trimetazidine, doping sparks fairness concerns ahead of Paris Olympics The World Anti-Doping Agency is under scrutiny for its decision to clear 23 Chinese swimmers to compete at the 2021 Tokyo ...

Kamila Valieva's trimetazidine case is the controversy of the 2022 Olympics, but the performance-enhancing drug has been long connected to sports. Here's what it is and why it is banned.

Trimetazidine is banned under the category of ‘hormone and metabolic modulators’ and is prohibited “in- and ...

The antianginal drug available in most of the world, but not in the US, may improve LVEF, functional capacity, and ventricular dimensions in patients with HF, suggests a meta-analysis.